Verastem (VSTM) Stock Analysis & AI Equity Report

Medical - Pharmaceuticals USD Explore free reports

Verastem (VSTM) overview

Verastem (VSTM) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 30.9m and operating profit of USD -170m; the year-end share price was 7.72 USD and market capitalisation was USD 600m. Verastem is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Verastem's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 57.2mFY 2025
Share price7.72 USDFY 2025 year end
RevenueUSD 30.9mFY 2025
Operating profitUSD -170mFY 2025
Net earningsUSD -209mFY 2025
Market capitalisationUSD 600mFY 2025 year end

About Verastem

Verastem is a biopharmaceutical company that develops and commercializes medicines for cancers driven by RAS/MAPK pathways. It markets AVMAPKI FAKZYNJA CO-PACK in the United States for adults with KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy. Its pipeline includes clinical-stage and preclinical drug programs, including treatments under evaluation for other cancers.

Generate the Verastem report

Verastem is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Verastem and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Verastem

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.